These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23110441)

  • 1. MS2 viruslike particles: a robust, semisynthetic targeted drug delivery platform.
    Galaway FA; Stockley PG
    Mol Pharm; 2013 Jan; 10(1):59-68. PubMed ID: 23110441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids.
    Wu M; Sherwin T; Brown WL; Stockley PG
    Nanomedicine; 2005 Mar; 1(1):67-76. PubMed ID: 17292060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles.
    Pan Y; Zhang Y; Jia T; Zhang K; Li J; Wang L
    FEBS J; 2012 Apr; 279(7):1198-208. PubMed ID: 22309233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles.
    Ashley CE; Carnes EC; Phillips GK; Durfee PN; Buley MD; Lino CA; Padilla DP; Phillips B; Carter MB; Willman CL; Brinker CJ; Caldeira Jdo C; Chackerian B; Wharton W; Peabody DS
    ACS Nano; 2011 Jul; 5(7):5729-45. PubMed ID: 21615170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production in Saccharomycescerevisiae of MS2 virus-like particles packaging functional heterologous mRNAs.
    Legendre D; Fastrez J
    J Biotechnol; 2005 May; 117(2):183-94. PubMed ID: 15823407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the Thermal Stability of Bacteriophage MS2-Derived Virus-like Particle and Its Engineered Variant.
    Vishwakarma P; Puri S; Banerjee M; Chang CY; Chang CC; Chaudhuri TK
    ACS Biomater Sci Eng; 2024 Aug; 10(8):4812-4822. PubMed ID: 38976823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
    Spagnou S; Miller AD; Keller M
    Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide.
    Wei B; Wei Y; Zhang K; Wang J; Xu R; Zhan S; Lin G; Wang W; Liu M; Wang L; Zhang R; Li J
    Biomed Pharmacother; 2009 May; 63(4):313-8. PubMed ID: 18823738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The three-dimensional structure of genomic RNA in bacteriophage MS2: implications for assembly.
    Toropova K; Basnak G; Twarock R; Stockley PG; Ranson NA
    J Mol Biol; 2008 Jan; 375(3):824-36. PubMed ID: 18048058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel delivery platform based on Bacteriophage MS2 virus-like particles.
    Fu Y; Li J
    Virus Res; 2016 Jan; 211():9-16. PubMed ID: 26415756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-specific delivery of bacteriophage-encapsidated ricin A chain.
    Wu M; Brown WL; Stockley PG
    Bioconjug Chem; 1995; 6(5):587-95. PubMed ID: 8974458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery.
    Shen Y; Wang B; Lu Y; Ouahab A; Li Q; Tu J
    Int J Pharm; 2011 Jul; 414(1-2):233-43. PubMed ID: 21545832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRR1 coat protein binding to its RNA translational operator.
    Persson M; Tars K; Liljas L
    Acta Crystallogr D Biol Crystallogr; 2013 Mar; 69(Pt 3):367-72. PubMed ID: 23519411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA bacteriophage capsid-mediated drug delivery and epitope presentation.
    Brown WL; Mastico RA; Wu M; Heal KG; Adams CJ; Murray JB; Simpson JC; Lord JM; Taylor-Robinson AW; Stockley PG
    Intervirology; 2002; 45(4-6):371-80. PubMed ID: 12602361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-plasmid double-expression His-tag system for rapid production and easy purification of MS2 phage-like particles.
    Mikel P; Vasickova P; Kralik P
    Sci Rep; 2017 Dec; 7(1):17501. PubMed ID: 29235545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a transferrin receptor-targeting HVJ-E vector.
    Shimbo T; Kawachi M; Saga K; Fujita H; Yamazaki T; Tamai K; Kaneda Y
    Biochem Biophys Res Commun; 2007 Dec; 364(3):423-8. PubMed ID: 17961511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo.
    Choi KM; Kim K; Kwon IC; Kim IS; Ahn HJ
    Mol Pharm; 2013 Jan; 10(1):18-25. PubMed ID: 22663765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Effects of Intersubunit Interface Mutations on Virus-Like Particle Structure and Stability.
    Pistono PE; Xu J; Huang P; Fetzer JL; Francis MB
    Biochemistry; 2024 Aug; 63(15):1913-1924. PubMed ID: 39037053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Surface Modification of Genome-Free MS2 Capsids for Delivery Applications.
    Aanei IL; Francis MB
    Methods Mol Biol; 2018; 1776():629-642. PubMed ID: 29869270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new RNA vaccine platform based on MS2 virus-like particles produced in Saccharomyces cerevisiae.
    Sun S; Li W; Sun Y; Pan Y; Li J
    Biochem Biophys Res Commun; 2011 Apr; 407(1):124-8. PubMed ID: 21362402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.